Gestational weight gain and health-related quality of life during pregnancy and the early postpartum period in women with cystic fibrosis receiving elexacaftor/tezacaftor/ivacaftor.
BACKGROUND Highly effective CFTR modulator therapy, such as elexacaftor/tezacaftor/ivacaftor (ETI), has significantly increased pregnancy rates in women with cystic fibrosis (wwCF). Data on health-related quality of life (HRQoL) during pregnancy and the early postpartum period under ETI remain limited. METHODS This r...